Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in anti-NMDA receptor encephalitis
NL-OMON59291Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anti-NMDA receptor encephalitis comparing Inebilizumab plus standard care with Placebo plus standard care (2 arms). Primary endpoints: Change in modified Rankin Scale at 16 weeks and Safety through 24 weeks. Started Dec 2024; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
anti-NMDA receptor encephalitis
Beyond the preview
Go deeper on NL-OMON59291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59291.